High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorFondazione IRCCS Istituto Nazionale dei Tumori, Milano
About this trial
The SARveillance trial is an efficient, pragmatic, multi-centre, international, stratified, partially-randomised, patient-preference trial within a registry of high versus lower intensity radiological surveillance following primary resection of retroperitoneal, abdominal and pelvic soft tissue sarcoma. The trial design is stratified by sarcoma tumour grade (high/intermediate grade and low grade).
Eligibility criteria
Qualifiers
Adult patients (greater than 18 years)
Primary resection
Histologically confirmed retroperitoneal, abdominal or pelvic soft tissue sarcoma
R0/R1 resection
Disqualifiers
Metastatic disease at time of randomisation
Recurrent, metastatic or residual disease identified on baseline CT imaging (3-4 months post primary resection)
Reoperation for recurrent soft tissue sarcoma
Re-resection following previous inadequate surgery
Trial design
Treatments tested in this trial
- High-intensity radiological surveillance
- Lower-intensity radiological surveillance
Treatment groups
584 Participants
are divided into 2 treatment groupsSponsors and collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lead sponsor
University of Birmingham
Collaborator
University Hospital Birmingham NHS Foundation Trust
Collaborator
Royal Marsden NHS Foundation Trust
Collaborator
University Hospital Padova
Collaborator
Campus Bio-Medico University
Collaborator
The Netherlands Cancer Institute
Collaborator
KU Leuven
Collaborator
Heidelberg University
Collaborator
Dana-Farber/Brigham and Women's Cancer Center
Collaborator
Emory University
Collaborator
Mayo Clinic
Collaborator
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Collaborator
The Cleveland Clinic
Collaborator
M.D. Anderson Cancer Center
Collaborator
University of Southern California
Collaborator
Ohio State University
Collaborator
Ottawa Hospital Research Institute
Collaborator
McGill University
Collaborator
Peter MacCallum Cancer Centre, Australia
Collaborator
Royal Prince Alfred Hospital, Sydney, Australia
Collaborator
Source ClinicalTrials.gov